Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study

References

• HerbstRSHeymachJVLippmanSMLung cancerN Engl J Med2008359131367138018815398
   PubMed Web of Science ®Google Scholar
• GouvinhasCDe MelloRAOliveiraDLung cancer: a brief review of epidemiology and screeningFuture Oncol201814656757529417838
   PubMed Web of Science ®Google Scholar
• GoldstrawPBallDJettJRNon-small-cell lung cancerLancet201137898041727174021565398
   PubMed Web of Science ®Google Scholar
• BerhouneMBanuEScotteFPrognonPOudardSBonanBTherapeutic strategy for treatment of metastatic non-small cell lung cancerAnn Pharmacother200842111640165218957625
   PubMed Web of Science ®Google Scholar
• HerbstRSMorgenszternDBoshoffCThe biology and management of non-small cell lung cancerNature2018553768944645429364287
   PubMed Web of Science ®Google Scholar
• RiihimäkiMHemminkiAFallahMMetastatic sites and survival in lung cancerLung Cancer2014861788425130083
   PubMed Web of Science ®Google Scholar
• QuintLETummalaSBrissonLJDistribution of distant metastases from newly diagnosed non-small cell lung cancerAnn Thorac Surg19966212462508678651
   PubMed Web of Science ®Google Scholar
• D’AntonioCPassaroAGoriBBone and brain metastasis in lung cancer: recent advances in therapeutic strategiesTher Adv Med Oncol20146310111424790650
   PubMed Web of Science ®Google Scholar
• DaweDEGreenspoonJNEllisPMBrain metastases in non-small-cell lung cancerClin Lung Cancer201415424925724954227
   PubMed Web of Science ®Google Scholar
• TaimurSEdelmanMJTreatment options for brain metastases in patients with non-small-cell lung cancerCurr Oncol Rep20035434234612781078
   PubMedGoogle Scholar
• WaqarSNSamsonPPRobinsonCGNon-small-cell lung cancer with brain metastasis at presentationClin Lung Cancer2018194e373e37929526531
   PubMed Web of Science ®Google Scholar
• UlahannanDKhalifaJFaivre-FinnCLeeSMEmerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges aheadAnn Oncol201728122923293129045549
   PubMed Web of Science ®Google Scholar
• MulvennaPMThe management of brain metastases in patients with non-small cell lung cancer – is it time to go back to the drawing board?Clin Oncol (R Coll Radiol)201022536537320395118
   PubMed Web of Science ®Google Scholar
• TsakonasGDe PetrisLEkmanSManagement of brain metastasized non-small cell lung cancer (NSCLC) – from local treatment to new systemic therapiesCancer Treat Rev20175412213128254730
   PubMed Web of Science ®Google Scholar
• WonYKLeeJYKangYNStereotactic radiosurgery for brain metastasis in non-small cell lung cancerRadiat Oncol J201533320721626484304
   PubMedGoogle Scholar
• KhuntiaDBrownPLiJMehtaMPWhole-brain radiotherapy in the management of brain metastasisJ Clin Oncol20062481295130416525185
   PubMed Web of Science ®Google Scholar
• ZimmermannSDziadziuszkoRPetersSIndications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastasesCancer Treat Rev201440671672224759599
   PubMed Web of Science ®Google Scholar
• TabchiSKourieHRKlasterskyJConcurrent driver mutations/rearrangements in non-small-cell lung cancerCurr Opin Oncol201729211812228027105
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin–paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• BrownTBolandABagustAGefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2717921047494
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (optimal, CTONG-0802): a multicentre, open-label, randomised, Phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• HeonSYeapBYBrittGJDevelopment of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibClin Cancer Res201016235873588221030498
   PubMed Web of Science ®Google Scholar
• LeeYJChoiHJKimSKFrequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancerCancer201011651336134320066717
   PubMed Web of Science ®Google Scholar
• BhattVRKediaSKessingerAGantiAKBrain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutationsJ Clin Oncol201331253162316423897953
   PubMed Web of Science ®Google Scholar
• ShinDYNaIIKimCHParkSBaekHYangSHEGFR mutation and brain metastasis in pulmonary adenocarcinomasJ Thorac Oncol20149219519924419416
   PubMed Web of Science ®Google Scholar
• HeonSYeapBYLindemanNIThe impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutationsClin Cancer Res201218164406441422733536
   PubMed Web of Science ®Google Scholar
• IuchiTShingyojiMSakaidaTPhase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinomaLung Cancer201382228228724021541
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• ChenAPSetserAAnadkatMJGrading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0J Am Acad Dermatol20126751025103922502948
   PubMed Web of Science ®Google Scholar
• SimoffMJLallyBSladeMGSymptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20131435 Supple455Se497S23649452
   PubMed Web of Science ®Google Scholar
• WuYLZhouCChengYErlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a Phase II study (CTONG-0803)Ann Oncol201324499399923129122
   PubMed Web of Science ®Google Scholar
• YangJJZhouCHuangYIcotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (brain): a multicentre, Phase 3, open-label, parallel, randomised controlled trialLancet Respir Med20175970771628734822
   PubMed Web of Science ®Google Scholar
• ChenYYangJLiXFirst-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinomaCancer Sci2016107121800180527627582
   PubMed Web of Science ®Google Scholar
• MagnusonWJYeungJTGuillodPDGettingerSNYuJBChiangVLImpact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastasesInt J Radiat Oncol Biol Phys201695267367927034176
   PubMed Web of Science ®Google Scholar
• LiuYDengLZhouXConcurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA scoreOncotarget201786711130911131729340055
   PubMedGoogle Scholar
• MagnusonWJLester-CollNHWuAJManagement of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysisJ Clin Oncol201735101070107728113019
   PubMed Web of Science ®Google Scholar
• WelshJWKomakiRAminiAPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerJ Clin Oncol201331789590223341526
   PubMed Web of Science ®Google Scholar
• BanksWAFrom blood–brain barrier to blood–brain interface: new opportunities for CNS drug deliveryNat Rev Drug Discov201615427529226794270
   PubMed Web of Science ®Google Scholar
• UpadhyayRKDrug delivery systems, CNS protection, and the blood brain barrierBiomed Res Int2014201486926925136634
   PubMed Web of Science ®Google Scholar
• KhalifaJAminiAPopatSGasparLEFaivre-FinnCInternational Association for the Study of Lung Cancer Advanced Radiation Technology CommitteeBrain metastases from NSCLC: radiation therapy in the era of targeted therapiesJ Thorac Oncol201611101627164327343440
   PubMed Web of Science ®Google Scholar
• ZhangJYuJSunXMengXEpidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancerCancer Lett2014351161224861428
   PubMed Web of Science ®Google Scholar
• JohungKLYaoXLiFA clinical model for identifying radio-sensitive tumor genotypes in non-small cell lung cancerClin Cancer Res201319195523553223897899
   PubMed Web of Science ®Google Scholar
• SpanoJPFagardRSoriaJCRixeOKhayatDMilanoGEpidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectivesAnn Oncol200516218919415668269
   PubMed Web of Science ®Google Scholar
• ChangELWefelJSHessKRNeurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialLancet Oncol200910111037104419801201
   PubMed Web of Science ®Google Scholar
• HabetsEJDirvenLWiggenraadRGNeurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective studyNeuro Oncol201618343544426385615
   PubMed Web of Science ®Google Scholar
• YangWCXiaoFShihJYEpidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgeryRadiother Oncol2018126236837429111173
   PubMed Web of Science ®Google Scholar
• LinXDeAngelisLMTreatment of brain metastasesJ Clin Oncol201533303475348426282648
   PubMed Web of Science ®Google Scholar
• LinJJandialRNesbitABadieBChenMCurrent and emerging treatments for brain metastasesOncology (Williston Park)201529425025725952487
   PubMed Web of Science ®Google Scholar
• MalapelleURicciutiBBaglivoSOsimertinibRecent Results Cancer Res201821125727630069773
   PubMedGoogle Scholar
• VansteenkisteJReungwetwattanaTNakagawaKCNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA studyAnn Oncol201728suppl_10mdx782
   Google Scholar
• ChoBCChewaskulyongBLeeKHOsimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subsetJ Thorac Oncol20191419910630240852
   PubMed Web of Science ®Google Scholar